Expert Review of Anticancer Therapy

Article	Citations
Triple-negative breast cancer: promising prognostic biomarkers currently in development	99
TIM-3 pathway dysregulation and targeting in cancer	58
TKIs in combination with immunotherapy for hepatocellular carcinoma	54
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis	46
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy	43
Optimal treatment in locally advanced cervical cancer	32
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer	31
Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies	28
Pediatric relapsed acute myeloid leukemia: a systematic review	28
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies	27
Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy	26
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis	24
How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer	23
The role of the microbiome in drug resistance in gastrointestinal cancers	23
Is smoking an independent risk factor for developing cervical intra-epithelial neoplasia and cervical cancer? A systematic review and meta-analysis	23
Predicting pathological response to chemoradiotherapy for rectal cancer: a systematic review	20
Radiomics features as predictive and prognostic biomarkers in NSCLC	20
Pembrolizumab for advanced cervical cancer: safety and efficacy	20
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma	19
Surgical management of intrahepatic cholangiocarcinoma	18
Amivantamab for the treatment ofEGFRexon 20 insertion mutant non-small cell lung cancer	18
Pembrolizumab in the first-line treatment of advanced head and neck cancer	18
Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature	17
Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer	17
Immunosenescence, inflammaging, and cancer immunotherapy efficacy	17

The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs	17
A multimodal approach to cancer-related cachexia: from theory to practice	17
Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy	16
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer	16
Apoferritin: a potential nanocarrier for cancer imaging and drug delivery	16
MRI radiomics in the prediction of therapeutic response to neoadjuvant therapy for locoregionally advanced rectal cancer: a systematic review	15
Clear cell sarcoma: state-of-the art and perspectives	13
Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer	13
Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-19	13
Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis	13
Combined endocrine and targeted therapy in luminal breast cancer	13
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance	13
Clinical management of squamous cell carcinoma of the tongue: patients not eligible for free flaps, a systematic review of the literature	12
Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma	12
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	12
Advances in systemic therapy for the first-line treatment of unresectable HCC	12
Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives	11
Development of chemotherapeutics for unresectable advanced esophageal cancer	11
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma	11
Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement	11
Measurable residual disease in pediatric acute myeloid leukemia: a systematic review	11
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy	11
Cemiplimab for locally advanced and metastatic basal cell carcinoma	10
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	10
Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer	10
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview	10
The impact of nutritional status on pancreatic cancer therapy	10
The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies	10
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence	10
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype	10
Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors	10
Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method	10
Ribociclib plus fulvestrant in the treatment of breast cancer	10
Treatment of cervical cancer: overcoming challenges in access to brachytherapy	10
Glasdegib in newly diagnosed acute myeloid leukemia	9
Brain metastases in metastatic cancer: a review of recent advances in systemic therapies	9
Current androgen receptor antagonists under investigation for resistant prostate cancer	9
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma	9
Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy	9
Therapeutic options in thymomas and thymic carcinomas	9
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?	9
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem	9
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma	9
High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL)	9
Immune checkpoint inhibitors for recurrent endometrial cancer	9
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer	9
The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma	9
Factors associated with early lung cancer mortality: a systematic review	9
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma	9
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	8

The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems	8
Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis	8
Addressing the problem of overtreatment in breast cancer	8
Detection ofMETexon 14 skipping mutations in non-small cell lung cancer: overview and community perspective	8
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma	8
Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives	8
Evaluating new treatments for anaplastic thyroid cancer	8
Risk factors for the development of local recurrence in extremity soft-tissue sarcoma	8
Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials	8
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer	8
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer	8
Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion	8
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan	8
miRNA and mRNA expression profiling reveals potential biomarkers for metastatic cutaneous melanoma	8
Targeting the PI3K pathway in myeloproliferative neoplasms	8
Immune checkpoint inhibition in classical hodgkin lymphoma	8
Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor	8
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer	8
Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract	7
Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy	7
Impact of anti-cancer therapy on disease severity and mortality in cancer patients with COVID-19: a systematic review and meta-analysis	7
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	7
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	7
Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician’s guide	7
The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation	7
Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel	7
Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity	7
Immunotherapy as a partner for HER2-directed therapies	6
The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma	6
Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma	6
Overview and recent advances in the targeting of medulloblastoma cancer stem cells	6
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer	6
Management of breast cancer diagnosed during pregnancy: global perspectives	6
Real-world experience with trabectedin for the treatment of recurrent ovarian cancer	6
A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials	6
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy	6
Immunotherapy in urothelial cancer: current status and future directions	6
Developments in personalized therapy for metastatic renal cell carcinoma	6
Curative therapy for rectal cancer	6
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma	6
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic	6
The current clinical approach to difficult-to-treat basal cell carcinomas	6
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials	6
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement	6
Elranatamab: a new promising BispAb in multiple myeloma treatment	6
Effect of primary tumor resection on survival in patients with asymptomatic unresectable metastatic colorectal cancer: a systematic review and meta-analysis	6
Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity	5
Clinically-meaningful improvements in therapy for unresectable NSCLC	5
Locoregional therapy in breast cancer patients treated with neoadjuvant chemotherapy	5
Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis	5
Understanding resistance to immune checkpoint inhibitors in advanced breast cancer	5
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review	5
The current status of gene therapy in bladder cancer	5
The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research	5
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light	5
A classification based on tumor-stroma ratio and tumor budding for patients with muscle-invasive bladder cancer	5
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?	5
Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC	5
Effectiveness and application of artificial intelligence for endoscopic screening of colorectal cancer: the future is now	5
Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety	5
Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy	5
Management of trophoblastic tumors : review of evidence, current practice, and future directions	5
Oxygen therapy in traditional and immunotherapeutic treatment protocols of cancer patients: current reality and future prospects	5
Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?	5
A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer	5
Medullary thyroid carcinoma: a narrative historical review	5
Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy	5
Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis	5
Multidisciplinary approaches to cancer cachexia: current service models and future perspectives	5
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer	4
Promising novel therapies for relapsed and refractory testicular germ cell tumors	4
Current and emerging therapies for localized high-risk prostate cancer	4
The role of immunotherapy in fusion-driven lung cancer	4
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	4
Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance	4
Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy	4
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement	4
Lymph nodal radiotherapy in breast cancer: what are the unresolved issues?	4
Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events	4
Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches	4

Diagnostic accuracy of arterial spin labeling in differentiating between primary central nervous system lymphoma and high-grade glioma: a systematic review and meta-analysis	4
Human oncogenic viruses: an overview of protein biomarkers in viral cancers and their potential use in clinics	4
Integrating supportive care into the multidisciplinary management of lung cancer: we can’t wait any longer	4
Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need	4
Naltrexone at low doses (LDN) and its relevance to cancer therapy	4
Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma	4
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)	4
A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022	4
Emerging treatment options for prostate cancer	4
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment	4
Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?	4
New nonchemotherapy treatment options for cutaneous T-cell lymphomas	4
Hot topics in renal cancer pathology: implications for clinical management	4
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma	4
Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy	4
Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma	4
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review	4
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials	3
An update on local and systemic therapies for nonmelanoma skin cancer	3
Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics	3
The optimal management of brain metastases from gestational trophoblastic neoplasia	3
Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors	3
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy	3
Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy	3
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens	3
The use of real-world evidence to support FDA post-approval study requirements for oncology drugs	3
Locoregional recurrence in triple negative breast cancer: past, present, and future	3
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation	3
Radiolabeled FAPI in pancreatic cancer: can it be an additional value in the management of patients?	3
Clinical implications of lung neuroendocrine neoplasm classification	3
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer	3
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis	3
Proton therapy for thoracic malignancies: a review of oncologic outcomes	3
Patient stratification in hepatocellular carcinoma: impact on choice of therapy	3
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer	3
Overview and recent advances in incidental meningioma	3
High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes	3
The role of immune checkpoint inhibition in triple negative breast cancer	3
Factors influencing survival in metastatic castration-resistant prostate cancer therapy	3
The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized cont	3
EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022	3
Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review	3
Malignant peritoneal cytology in endometrial cancer: a contemporary review	3
Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review	3
Relugolix in the management of prostate cancer	3
How will artificial intelligence impact breast cancer research efficiency?	3
Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure	3
Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis	3
Increasing the accuracy of colorectal cancer screening	3
Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma	3
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis	3
Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer	3
Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis	3
Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin	3
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma	3
Diagnostic accuracy of diffusion-weighted imaging in differentiating glioma recurrence from posttreatment-related changes: a meta-analysis	3
Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma	3
20 years of Expert Review of Anticancer Therapy	3
Avelumab in locally advanced or metastatic urothelial carcinoma	2
Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management	2
Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis	2
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer	2
Technological advancements and future perspectives in breast cancer radiation therapy	2
Targeting human EGFR 2 (HER2) in salivary gland carcinoma	2
Implementing continued radiation therapy for cancer management in low resource countries during and after the COVID-19 crisis	2
Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy	2
The role of autophagy in acute myeloid leukemia development	2
Circadian rhythm-based cancer therapy in randomised clinical trials	2
Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?	2
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma	2
Immune checkpoint inhibition in early-stage triple-negative breast cancer	2
Ifosfamide-induced nephrotoxicity in oncological patients	2
The effect of mechanical force in genitourinary malignancies	2
Targeting the DNA damage response in pediatric malignancies	2
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas	2
Low CBS expression can identify patients who benefit from adjuvant chemotherapy in gastric cancer	2
Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view	2
Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: a population-based stud	2
Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors	2
Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder	2
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan	2
The clinical relationship between histamine-1 receptor antagonists and risk of cancer: a systematic review and meta-analysis	2
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer	2
The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management	2
Repurposing antipsychotic drugs for cancer treatment: current evidence and future perspectives	2
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia	2
Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies	2
Emerging treatment strategies in hepatobiliary cancer	2
Oligometastases in head and neck squamous cell carcinoma patients	2
Primary site and treatment impact in unresectable metastatic colorectal cancer	2
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium	2
The safety and efficacy of immunotherapy and palliative radiotherapy in patients with metastatic non-small cell lung cancer: a systematic review and meta-analysis of 13 prospective studies	2
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations	2
How can we better distinguish metastatic tumors from primary tumors in the breast?	2
Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer	2